(Q37775216)

23 August 2017

1 reference

title

GABAB receptors in addiction and its treatment (English)

1 reference

23 August 2017

4

David J Nutt

0 references

Anne Lingford-Hughes

series ordinal

2

object named as

Anne Lingford-Hughes

1 reference

23 August 2017

Robin J Tyacke

1

1 reference

23 August 2017

Laurence J Reed

series ordinal

3

1 reference

23 August 2017

publication date

1 January 2010

1 reference

23 August 2017

published in

Advances in Pharmacology

1 reference

23 August 2017

volume

58

1 reference

23 August 2017

page(s)

373-396

1 reference

Formulation of controlled-release baclofen matrix tablets. II. Influence of some hydrophobic excipients on the release rate and in vitro evaluation.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Rapid suppression of alcohol withdrawal syndrome by baclofen.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Suppression of alcohol delirium tremens by baclofen administration: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Reduced G-protein coupling to the GABAB receptor in the nucleus accumbens and the medial prefrontal cortex of the rat after chronic treatment with nicotine.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

A potential role for GABA(B) agonists in the treatment of psychostimulant addiction

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Suppression of symptoms of alcohol dependence and craving using high-dose baclofen.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Differential G-protein coupling to GABAB receptor in limbic areas of alcohol-preferring and -nonpreferring rats

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Severe gamma-hydroxybutyrate withdrawal: a case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

A novel strategy for the treatment of cocaine addiction

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Acute interaction of baclofen in combination with alcohol in heavy social drinkers

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Baclofen for alcohol dependence: a preliminary open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Tiagabine increases cocaine‐free urines in cocaine‐dependent methadone‐treated patients: results of a randomized pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

The effect of antiepileptic drugs on visual performance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Synthesis of (R,S)-[4-11C]baclofen via Michael addition of nitromethane labeled with short-lived 11C.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Baclofen-assisted detoxification from opiates. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: in vitro and in vivo evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Baclofen and gamma-hydroxybutyrate withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Chronic nicotine and smoke treatment modulate dopaminergic activities in ventral tegmental area and nucleus accumbens and the gamma-aminobutyric acid type B receptor expression of the rat prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

A retrospective chart review comparing tiagabine and benzodiazepines for the treatment of alcohol withdrawal.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Tiagabine affects the subjective responses to cocaine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

The irreversible gamma-aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

GABA, gamma-hydroxybutyric acid, and neurological disease

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2810%2958014-1

7 January 2021

10.1016/S1054-3589(10)58014-1

Identifiers

DOI

1 reference

23 August 2017

1 reference